Sinn Féin leader urges Taoiseach to intervene after HSE refusal to fund drug for rare diseaseSinn Féin leader Mary Lou McDonald has written to Taoiseach Micheál Martin requesting his intervention regarding the Health Service Executive's (HSE) decision not to fund the drug Skyclarys for Friedreich’s ataxia. The HSE Drugs Group rejected the drug due to limited clinical efficacy data, despite its approval in the EU and US. McDonald highlights the distress of patients and families, emphasizing the urgency of accessing the treatment, which could slow disease progression by up to 55%. She calls for transparency in the HSE's decision-making process and urges an urgent meeting between the Taoiseach, affected families, and HSE officials. The case reflects broader debates over healthcare funding and patient access to innovative treatments.
Bias read (Progressive): The article frames the issue through the lens of patient advocacy and criticizes the HSE's decision as being out of step with EU standards. It emphasizes the urgency and distress of patients, aligning with left-leaning priorities of patient rights and healthcare accessibility. While the HSE's stance
Why factuality (96): This article provides detailed information about the timeline of Skyclarys approval, the role of the NCPE, and the HSE Drugs Group's reasoning. These points are consistent with the other sources and provide additional context that supports the overall factual accuracy.
Why objectivity (88): The article remains mostly objective but includes quotes from Sinn Féin leader Mary Lou McDonald expressing concern for patients, which may introduce a slight bias toward the advocacy perspective. Still, it avoids strong editorializing.
TheJournal.ieIndependentProgressiveFactual 95Objective 909 days agoPressure is increasing on the Irish government to overturn a Health Service Executive (HSE) decision to deny funding for Skyclarys, the only licensed treatment for Friedreich’s Ataxia. A letter signed by 47 Fianna Fáil MPs, including junior justice minister Catherine Ardagh, has been sent to Health Minister Jennifer Carroll MacNeill and other officials, urging them to reject the HSE’s recommendation. The decision comes after a Fianna Fáil TD, John McGuinness, whose nephew suffers from the condition, expressed shock at the ruling. Friedreich’s Ataxia is a rare, inherited neurodegenerative disorder with no known cure, though Skyclarys has been shown to slow progression. Approved by the European Medicines Agency in February 2024, the drug is available in other European countries but not yet in Ireland. The HSE drugs group recommended against funding the treatment, citing cost considerations, and the final decision will be made by the HSE senior management team in early September.
Bias read (Progressive): The article frames the issue as a moral and ethical dilemma, emphasizing the human impact of the HSE’s decision and the political responsibility of the government to act. The focus on patient advocacy, emotional appeals, and the involvement of high-profile politicians like John McGuinness and Fianna
Why factuality (95): The article accurately reports the situation regarding the HSE's rejection of funding for Skyclarys, citing the involvement of Fianna Fáil MPs, the nature of the disease, and the availability of the drug elsewhere in Europe. All key facts align with the cross-source consensus from other articles.
Why objectivity (90): The article maintains a largely neutral tone, presenting the issue as a political concern raised by Fianna Fáil members without overtly favoring any side. However, the use of words like 'shocked' and 'pressure growing' slightly introduces subjective language, though not strongly biased.
RTÉ NewsState / PublicCenterFactual 95Objective 9011 days agoThe National Centre for Pharmacoeconomics (NCPE) stated that the cost of the drug Skyclarys for treating Friedreich's Ataxia would need to be significantly reduced for the HSE to cover it. Professor Michael Barry, Clinical Director of the NCPE, explained that the HSE's Drugs Group decided against recommending the drug due to its high cost, estimated at €160 million annually. He emphasized the challenge of balancing drug effectiveness with cost, noting that spending on Friedreich's Ataxia could affect funding for other treatments like cancer therapies. Around 200 people in Ireland live with the condition and have campaigned for the drug, while Biogen continues to engage with the HSE. A court case is ongoing regarding delayed access.
Bias read (Center): The article presents a balanced view of the decision-making process involving multiple stakeholders including the NCPE, HSE, patient advocates, and pharmaceutical companies. There is no overt ideological slant in the framing of the issue, nor is there a clear preference for one side over another. It
Why factuality (95): This article mirrors the first one closely, reporting the NCPE's stance on the drug's cost and the HSE's decision-making process. It includes accurate details about the HSE Drugs Group's meetings and the €160 million budget impact. The content aligns with the cross-source consensus and does not intr
Why objectivity (90): The article remains neutral in tone, quoting Prof Barry directly and presenting the situation objectively. It avoids taking sides and sticks to the facts reported by the NCPE and HSE.
RTÉ NewsState / PublicCenterFactual 95Objective 9011 days ago Cost cut needed to cover Friedreich's Ataxia drug - NCPEThe National Centre for Pharmacoeconomics (NCPE) stated that the cost of the drug Skyclarys for treating Friedreich's Ataxia would need to be significantly reduced for the Irish health service (HSE) to cover it. The HSE's Drugs Group rejected recommending the drug due to its high projected cost of €160 million. Professor Michael Barry, Clinical Director of the NCPE, emphasized the importance of considering opportunity costs and the broader financial pressures on the HSE, particularly regarding other treatments like cancer therapies. Around 200 people in Ireland live with Friedreich's Ataxia and have campaigned for the drug, facing disappointment after the decision. The drug, developed by Biogen, costs approximately €280,000 per patient annually, and a legal challenge is ongoing by one affected individual.
Bias read (Center): The article presents a balanced view of the situation, citing both the HSE's financial concerns and the advocacy efforts of patients and their supporters. While the issue involves healthcare policy and government spending, the reporting does not take a clear ideological stance. The focus is on the H
Why factuality (95): The article accurately reports the NCPE's position that a significant price reduction is needed for the drug to be covered by the HSE. It includes direct quotes from Prof Barry and provides context about the HSE's evaluation process, including consideration of patient input and other committees. The
Why objectivity (90): The article maintains a neutral tone, presenting facts and direct quotes without overt bias. While phrases like 'huge demands' and 'severe' may carry some emotional weight, they are presented as statements from Prof Barry rather than the author's own opinion.
Treatment for Friedreich's ataxia should not be funded by HSE, drugs group recommendsThe HSE Drugs Group has recommended against funding the drug Skyclarys for the treatment of Friedreich’s ataxia, citing concerns over cost and resource allocation. The recommendation follows a review of clinical evidence, patient impact, and financial implications. Skyclarys, approved by the European Medicines Agency in 2024, slows disease progression but costs approximately €280,000 per patient annually. Around 200 individuals in Ireland live with the condition, and advocates have campaigned for its availability through the HSE. The decision will be reviewed by HSE senior management before a final determination. The HSE emphasized the importance of balancing patient needs with healthcare resource constraints.
Bias read (Center): The article presents the HSE Drugs Group's recommendation as a balanced evaluation based on clinical, financial, and ethical considerations. While the issue of drug affordability and access is politically sensitive, the reporting does not overtly favor either side. The HSE's statement acknowledges患者
Why factuality (95): The article accurately conveys the HSE Drugs Group's recommendation against funding the drug and provides relevant background on Friedreich’s ataxia and Skyclarys. It mentions the €280,000 annual cost per patient and the timeline of approvals, aligning with other sources. The reference to the NCPE's
Why objectivity (85): The article presents the facts neutrally but includes a photo of protesters, which may subtly influence reader perception. However, the text itself remains largely objective, focusing on the HSE's rationale and the patient perspective without overtly favoring either side.
RTÉ NewsState / PublicProgressiveFactual 95Objective 8515 days ago Call over access to drug to treat Friedreich's AtaxiaSinn Féin leader Mary Lou McDonald has urged the Irish government to expedite access to Skyclarys, the first and only EU-approved drug for Friedreich's Ataxia, a rare neurological disorder. She criticized the potential for further bureaucratic delays, emphasizing the urgency due to the disease's progressive nature. Clinical trials show the drug could slow symptom progression, though it is currently publicly funded in some European countries. A campaigner, Emily Felix, has taken legal action against the Health Service Executive (HSE) over reimbursement delays, with the High Court allowing her to pursue a judicial review. The HSE stated it would consider the drug's cost-effectiveness and budget implications before making a decision.
Bias read (Progressive): The article frames the issue through the lens of patient advocacy and government accountability, highlighting concerns about bureaucratic delays and the urgent need for treatment. While the subject is a health issue, the emphasis on political responsibility and the critique of administrative inertia
Why factuality (95): The article accurately reports the situation regarding Skyclarys and Friedreich's Ataxia, citing specific details such as the drug being the first and only EU-authorized treatment, the involvement of Sinn Féin leader Mary Lou McDonald, and the legal action taken by Emily Felix. It aligns closely wit
Why objectivity (85): The article presents the issue from the perspective of the patient advocacy group and political figures, emphasizing urgency and the need for government action. While it does highlight the concerns of those affected, it avoids overtly biased language and maintains a generally neutral tone.
RTÉ NewsState / PublicProgressiveFactual 94Objective 899 days ago Fianna Fáil letter challenges HSE stance on rare disease drugA letter signed by 48 members of the Fianna Fáil parliamentary party, including one Minister of State, raises serious concerns about the Health Service Executive's (HSE) decision to recommend against funding Skyclarys, a drug used to treat Friedreich’s Ataxia. The letter criticizes the HSE's reimbursement process as 'broken and not fit for purpose' and urges leaders like Taoiseach Micheál Martin and Health Minister Jennifer Carroll MacNeill to ensure access to the drug for affected families. Friedreich’s Ataxia affects approximately 200 people in Ireland, and Skyclarys is the only approved treatment, capable of slowing symptom progression by up to 50%. Despite a favorable report from the Rare Diseases Technology Review Committee, the HSE Drugs Group has twice recommended against reimbursement, citing cost considerations.
Bias read (Progressive): The article frames the issue as a failure of the HSE's reimbursement system, highlighting the political pressure from Fianna Fáil members to secure access to the drug. While the HSE cites financial constraints, the article emphasizes the human impact and the potential for political intervention, til
Why factuality (94): The article accurately describes the Fianna Fáil letter, the number of signatories, and the financial implications of the drug. It aligns closely with the other articles, though it lacks specific mention of the NCPE's role, which is covered in another article.
Why objectivity (89): The article presents the situation neutrally, focusing on the actions taken by Fianna Fáil members. It avoids taking sides but does include a quote suggesting the system is 'broken,' which could be seen as a mild opinion rather than an objective statement.
Fianna Fáil revolt over HSE refusal to reimburse drug for Friedreich’s ataxia patientsFianna Fáil, a major political party in Ireland, has expressed strong opposition to the Health Service Executive (HSE)'s decision to refuse reimbursement for a specific drug used to treat Friedreich’s ataxia, a rare genetic disorder. This issue has sparked internal dissent within the party, highlighting concerns over patient access to essential treatments. The controversy centers around whether the HSE's decision aligns with public health priorities and ethical obligations toward patients with rare conditions. The situation reflects broader debates about healthcare funding, pharmaceutical accessibility, and the role of government in ensuring equitable treatment options.
Bias read (Progressive): The framing emphasizes the political backlash against the HSE's decision, suggesting that the refusal to reimburse the drug is being criticized by a major leftist party. The focus on patient rights and healthcare accessibility aligns with progressive values, while the emphasis on dissent within Fi安娜
Why factuality (90): The title suggests a 'revolt' within Fianna Fáil, which is supported by the other articles. However, the body of the article is incomplete, so the level of detail is limited compared to the others. Despite this, the core facts match the cross-source consensus.
Why objectivity (85): Due to the lack of full text, the objectivity score is lower. The title implies a stronger stance, potentially introducing a more activist tone. Without the full content, it's harder to assess neutrality definitively.
Treatment for Friedreich’s ataxia should not be reimbursed by HSE, drug group recommendsA drug group in Ireland has recommended that the Health Service Executive (HSE) should not reimburse the treatment Skyclarys for Friedreich’s ataxia, citing high costs and uncertainty over its effectiveness. Friedreich’s ataxia is a rare genetic disorder causing progressive nerve damage and reduced life expectancy. Although the drug was approved in the U.S. in 2023 and in Europe in 2024, it remains unavailable through the HSE in Ireland. The National Centre for Pharmacoeconomics (NCPE) assessed the drug’s cost-effectiveness and concluded it would cost approximately €280,000 per patient annually. The HSE Drugs Group reviewed the application and decided against reimbursement, noting limitations in clinical data and the drug’s high price relative to typical cost-effectiveness standards. Patients and advocacy groups continue to push for access, with one individual seeking legal action against the HSE for delaying the decision.
Bias read (Center): The article presents information from both the HSE and advocacy groups without overtly favoring either side. While the issue involves healthcare policy and public funding decisions, which are politically sensitive, the reporting does not exhibit clear ideological leaning. The framing remains neutral
Why factuality (90): The article accurately summarizes the HSE Drugs Group's non-recommendation for reimbursement and provides context on the drug's approval status and cost. It references the NCPE's earlier assessment and the ongoing patient advocacy efforts. Minor discrepancies exist in the timing of the drug's approv
Why objectivity (85): The article is generally neutral but includes a headline that emphasizes the HSE's rejection, which may slightly frame the issue as a negative outcome for patients. Despite this, the body of the article presents both the HSE's reasoning and the patient perspective fairly.
RTÉ NewsState / PublicCenterFactual 85Objective 7812 days ago HSE to consider covering cost of Friedreich's Ataxia drugThe HSE Drugs Group in Ireland is set to reconsider whether to cover the cost of Skyclarys, a drug that can slow the progression of Friedreich's Ataxia. Around 200 individuals live with this rare neurological condition and have been actively campaigning for the drug's availability through the healthcare system. Initially, the HSE Drugs Group recommended against covering Skyclarys due to concerns over cost-effectiveness, citing a €280,000 annual cost per patient and a potential five-year budget impact of €130 million. However, a review by the Rare Diseases Technology Review Group now suggests the drug's introduction. The final decision will be made after today’s meeting and will go before the HSE Senior Management Team on 25 August. Campaigners have lobbied politicians and recently met with Health Minister Jennifer Carroll MacNeill, while Biogen, the drug manufacturer, continues discussions with the HSE. A legal challenge is also underway by one affected individual seeking access to the medication.
Bias read (Center): The article presents information about a policy decision regarding drug coverage without overtly favoring either side. It includes perspectives from campaigners, officials, and the pharmaceutical company, and reports on both the initial rejection and the new review. There is no clear ideological sl抗
Why factuality (85): The article accurately reports the HSE Drugs Group's reconsideration of Skyclarys coverage, citing the Rare Diseases Technology Review Group's support and the previous NCPE recommendation against cost-effectiveness. It provides context about the disease, the drug's approval status, and the financial
Why objectivity (78): The tone remains neutral, presenting both sides of the debate (previous recommendation vs. new review) and mentioning campaign efforts without taking an explicit stance. However, there is slight emphasis on the significance of the issue during Ireland's EU presidency, which may slightly skew focus.
Ireland
